Referred to the House Committee on Ways and Means.
Creates two new tax credits to encourage domestic production and investment in generic drugs and biosimilars. The production credit (Section 45BB) pays a percentage of value added for eligible components made and sold in the U.S., with a domestic-content bonus and a phase-out after 2030.
Liberals stress affordability and worker/environmental safeguards absent from text
Sectoral tax incentives often find House support, but fiscal scrutiny and competing tax priorities raise resistance.
Creates two new tax credits to encourage domestic production and investment in generic drugs and biosimilars.
The production credit (Section 45BB) pays a percentage of value added for eligible components made and sold in the U.S., with a domestic-content bonus and a phase-out after 2030.
The investment credit (Section 48F) provides a 25% credit for qualified property in facilities producing eligible components, with an expiration for construction after 2028.
Moderate bipartisan appeal on domestic manufacturing but significant fiscal cost, complexity, and temporary windows reduce standalone passage odds.
How solid the drafting looks.
Liberals stress affordability and worker/environmental safeguards absent from text
These are examples from the analysis, not a ranked list of the most-affected groups.
Liberals stress affordability and worker/environmental safeguards absent from text
Likely supportive overall because the bill strengthens domestic manufacture of generics and biosimilars, improving access and supply chain resilience.
Concerned that credits do not require price or access protections, labor standards, or environmental safeguards.
Would want stronger conditions tying subsidies to affordability and worker protections.
Generally favorable as a targeted, time-limited fiscal incentive to boost supply resilience and domestic investment.
Wants safeguards against abuse, clear reporting, and measurable performance metrics to justify fiscal cost.
Views phase-outs and documentation rules as useful but seeks enforcement clarity.
Skeptical because it creates targeted tax incentives that resemble industry subsidies and could increase deficits.
May support the goal of domestic production for national security, but prefers market-based, minimal-intervention approaches.
Likely to demand tighter limits, offsets, and shorter durations.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Moderate bipartisan appeal on domestic manufacturing but significant fiscal cost, complexity, and temporary windows reduce standalone passage odds.
The bill has not accumulated any surfaced votes yet.
Liberals stress affordability and worker/environmental safeguards absent from text
Moderate bipartisan appeal on domestic manufacturing but significant fiscal cost, complexity, and temporary windows reduce standalone passa…
Pro readers get the full perspective split, passage barriers, legislative design review, stakeholder impact map, and lens-based policy tradeoff analysis for PILLS Act.
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.